“安吉丽娜效应”影响迅速且持续时间长
Referrals for genetic counselling and testing for breast cancer risk more than doubled across the UK after actress Angelina Jolie announced in May last year that she tested positive for a BRCA1 gene mutation and underwent a double mastectomy. The rise in referrals continued through to October long after the announcement was made. This is according to research published in the journal Breast Cancer Research. New research based on data from 21 centers shows that many more women approached their GPs with concerns. Far from these being women with unfounded concerns, it was women with a family history of breast cancer, which translated into appropriate referrals for testing. This research was funded by Breast Cancer Campaign.
BRCA1 mutation is inherited from a parent, and is the cause of at least ten per cent of breast cancers. Women who have the BRCA1 gene mutation have between 45 per cent and 90 per cent risk of developing breast cancer in their lifetime. If you have a strong family history of breast cancer and a living relative with breast cancer, it is possible to test for the mutation. Clinical guidance in the UK, which was published not long after Angelina Jolie made her announcement last year, recommends that only women who are at a greater risk of developing breast cancer should be referred for genetic testing at a family history clinic or a regional genetics center.
News stories can have short-term effect on health-seeking behavior, but researchers led by Gareth Evans, from Genesis Breast Cancer Prevention and St Mary's Hospital, Manchester, wanted to see if there was a lasting effect. They assessed data from 12 family history clinics and 9 regional genetic centres in the UK. They found that there was a two and a half-fold increase in referrals by their GPs for June and July 2013 immediately after the actress' announcement, compared to the same two months in 2012. This rise in referrals continued from August to October with a two-fold increase over the same period the previous year. The researchers believe that during this period of increased interest, there was no greater proportion of inappropriate referrals by GPs.
Gareth Evans, professor of clinical genetics at Genesis Breast Cancer Prevention, says: "Although there was concern that the increase in attendance following Ms Jolie's announcement might have been from the 'worried well' coming back for an early repeat screen, our research found that the opposite was true. A higher proportion was from women who were late for their test, rather than those who were coming back early."